ReviewMolecular medicine reports2026
TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The poor prognosis of high‑grade gliomas, such as glioblastoma, is largely driven by a notably immunosuppressive tumor microenvironment (TME), wherein microglia and tumor‑associated macrophages play important roles. The present review summarizes the current evidence supporting triggering receptor expressed on myeloid cells 2 (TREM2) as a key immunoregulator in the glioma TME. The present review explores the context‑dependent dual role of TREM2, which can either be hijacked to promote immunosuppression and tumor progression or inhibit tumor progression through its notable functions in phagocytosis and antigen presentation. The present review also examines the clinical association of TREM2 expression with glioma grade and patient prognosis, evaluating its potential as a diagnostic and prognostic biomarker. Furthermore, the present review discusses the current landscape of TREM2‑targeted therapeutic strategies, from direct TREM2 inhibition and myeloid‑targeted immunocytokines to nano‑engineered drug delivery systems, and addresses the core translational challenges of these strategies. Looking forward, the importance of leveraging spatial multi‑omics and artificial intelligence to decipher the functional heterogeneity of TREM2 and to guide precision immunotherapy is highlighted. In conclusion, the present review provides a comprehensive framework for understanding the role of TREM2 in glioma; this receptor serves not only as a biomarker for glioma, but as an important signaling hub in the glioma TME. Therefore, the present review aims to support the development of novel therapeutic strategies targeting the immune microenvironment in glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.